Duchenne/Becker and FSH Muscular Dystrophies Receive ICD-10 Codes

Parent Project Muscular Dystrophy, FSH Society Lead Effort to Obtain Critical Diagnostic Classification Standard HACKENSACK, N.J., Dec. 7, 2017 /PRNewswire-USNewswire/ — Parent Project Muscular Dystrophy (PPMD), along with collaborators the FSH Society and the Foundation to Eradicate Duchenne (FED), are pleased to announce that the nominations to create more specific ICD-10 codes for Duchenne/Becker muscular … Read more of “Duchenne/Becker and FSH Muscular Dystrophies Receive ICD-10 Codes” »

Focus on Fulcrum’s FSHD tissue modeling project

Cambridge, Massachusetts, biotech company Fulcrum Therapeutic’s research program on FSH muscular dystrophy was featured in Clinical Leader yesterday. The company “is using tissue donated from patients with facioscapulohumeral (FSH) muscular dystrophy, an incurable form of the disease, to find a treatment,” the article reported. “The tissue is used to create research models that look and respond … Read more of “Focus on Fulcrum’s FSHD tissue modeling project” »

Recent FSHD research publications

Notable findings and advances from the past six months by DANIEL PAUL PEREZ Chief Science Officer, FSH Society Asterisk denotes FSH Society funding acknowledged in paper. “Conservation and innovation in the DUX4-family gene network,” from the laboratory of Stephen J. Tapscott at the Fred Hutchinson Cancer Center in Seattle, Washington (Whiddon et al. Nat Genet. … Read more of “Recent FSHD research publications” »

Charity Navigator rates FSH Society as “Exceptional”

The FSH Society has earned its tenth consecutive 4-star Charity Navigator rating! According to Michael Thatcher, President & CEO of Charity Navigator, “Only 1% of the charities we rate have received at least 10 consecutive 4-star evaluations, indicating that FSH Society outperforms most other charities in America. This “Exceptional” designation from Charity Navigator differentiates FSH … Read more of “Charity Navigator rates FSH Society as “Exceptional”” »

An undeniable sense of optimism

In this interview, Dr. Jeffery Statland of the University of Kansas Medical Center explains how FSH Society funding seeded the creation of the seven-site Clinical Trial Research Network (CTRN), which in turn led to the largest clinical trial preparedness study that has ever been run in the United States. We have entered a convergence zone―a … Read more of “An undeniable sense of optimism” »

A comedian’s worst nightmare

Watch what happens with this famous Dutch comedian performs before an audience of people with facioscapulohumeral muscular dystrophy.  Did you notice confidence and determination of these patients and families, boldly demanding recognition and action on FSHD? We know the direction we need to go. That’s why you can donate with confidence to the FSH Society’s … Read more of “A comedian’s worst nightmare” »

Placing a BET on blocking DUX4

by FRAN SVERDRUP, PHD St. Louis, Missouri DUX4 is considered to be a key cause of muscle degeneration in FSH muscular dystrophy. This is why we are interested in finding drugs that “turn off” the production of DUX4, which would prevent the many detrimental activities of this toxic protein. Such drugs would potentially provide the … Read more of “Placing a BET on blocking DUX4” »

Nearly $1.2 million committed in 2017 to FSH muscular dystrophy research

The FSH Society has awarded grants totaling $616,467 to seven research projects submitted during the February 2017 grant cycle. This brings the Society’s total new research commitments to $1,167,260 for the year. Reviewed by the Society’s world-class Scientific Advisory Board, these cutting-edge projects will help to accelerate the development of treatments. Michael Kyba’s project will carry … Read more of “Nearly $1.2 million committed in 2017 to FSH muscular dystrophy research” »